Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.5
Journals
Processes
Special Issues
Application of Nanoparticles in Cancer Therapy
share announcement

Application of Nanoparticles in Cancer Therapy

A special issue of Processes (ISSN 2227-9717). This special issue belongs to the section "Pharmaceutical Processes".

Deadline for manuscript submissions: closed (20 August 2023) | Viewed by 19292

Special Issue Editors

Prof. Dr. Vilma Petrikaite

E-Mail Website
Guest Editor
Laboratory of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50162 Kaunas, Lithuania
Interests: functionalized nanomaterials; targeted cancer treatment; cancer 2D and 3D models; transport in tumor microenvironment
Prof. Dr. Christian Celia

E-Mail Website
Guest Editor
Department of Pharmacy, University of Chieti—Pescara “G. d’Annuzio”, 66100 Chieti, Italy
Interests: liposomes; hybrid nanoparticles; drug delivery; nanoparticles; anticancer drugs; active targeting

Special Issue Information

Dear Colleagues,

Paul Ehrlich’s magic bullets was a scientific concept developed in Germany in 1900, and explored the opportunity to kill specific microbes (such as bacteria) causing different pathologies in the body using magic bullets or nanoparticles that can target specific microbes, releasing payloads that accumulate in selected microbe compartments. Based on this concept, researchers have attempted to develop smart and complex nanoparticles that can use specific markers of pathologies to deliver therapeutic agents to the targeted pathological tissues. This strategy has allowed for a decrease in the side effects of therapeutics and increased their efficacy both in vitro and in vivo. The reduction of side effects and the opportunity to use a low therapeutic dosage of drugs has significant therapeutic implications for use both in vitro and in vivo, as well as for patients, and has been especially advantageous in cancer therapy. In fact, cancer protocols and clinical trials sometimes fail due to unspecific responses of the patient to therapy, or the occurrence of side effects that irreparably compromise the efficacy of therapy and the clinical status of patients. Nanoparticles composed of different biomaterials represent a valid option for overcoming these drawbacks in moving from the bench to the bedside, thus offering scientists and patients the opportunity to use nanoparticles as specific tools for cancer therapy.

This Special Issue on “Application of Nanoparticles in Cancer Therapy” seeks high-quality work focusing on the latest advances of nanotechnology applied in cancer therapy area. Topics include, but are not limited to:

  • Development of new nanomaterials for cancer therapy;
  • Development of nanocarriers for personalized and precision medicine;
  • Design of lipid/polymer/hybrid nanocarriers targeting for cancer therapy;
  • Design of new macromolecules and derivatives for cancer therapy;
  • Investigations of alternative therapeutic strategies involving nanocarriers for cancer therapy;
  • Investigations on the translational aspects and scale-up of nanocarriers for cancer therapy.

Prof. Dr. Vilma Petrikaite
Prof. Dr. Christian Celia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Processes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • liposomes
  • functionalized nanomaterials
  • cancer therapy
  • tumor microenvironment
  • drug delivery
  • nanomedicine
  • nanotechnology

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 2073 KiB  
Article
Iron Oxide/Salicylic Acid Nanoparticles as Potential Therapy for B16F10 Melanoma Transplanted on the Chick Chorioallantoic Membrane
by Maria Cristina Predoi, Ion Mîndrilă, Sandra Alice Buteică, Ștefana Oana Purcaru, Dan Eduard Mihaiescu and Ovidiu Marcel Mărginean
Processes 2020, 8(6), 706; https://doi.org/10.3390/pr8060706 - 19 Jun 2020
Cited by 8 | Viewed by 2384
Abstract
Unfavorable prognoses and low survival rates are specific features of metastatic melanoma that justify the concern for the development of new therapeutic strategies. Lately, nanotechnology has become an attractive field of study due to recent advances in nanomedicine. Using a chick chorioallantoic membrane [...] Read more.
Unfavorable prognoses and low survival rates are specific features of metastatic melanoma that justify the concern for the development of new therapeutic strategies. Lately, nanotechnology has become an attractive field of study due to recent advances in nanomedicine. Using a chick chorioallantoic membrane (CAM) implanted with xenografts harvested from C57BL/6 mice with B16F10 melanoma cells, we studied the effects of iron oxide nanoparticles functionalized with salicylic acid (SaMNPs) as a form of therapy on the local development of xenotransplants and CAM vessels. The SaMNPs induced an anti-angiogenic effect on the CAM vessels, which accumulated preferentially in the melanoma cells and induced apoptosis and extensive xenograft necrosis. As a result, this slowed the increase in the xenograft volume and reduced the melanoma cells’ ability to metastasize locally and distally. Further, we demonstrate the use of the chick CAM model as a tool for testing the action of newly synthesized nanocomposites on melanoma xenotransplants. The SaMNPs had a therapeutic effect on B16F10 melanoma due to the synergistic action of the two components of its structure: the coating of the salicylic acid with antiangiogenic and chemotherapeutic action and the core of iron oxides with cytotoxic action. Full article
(This article belongs to the Special Issue Application of Nanoparticles in Cancer Therapy)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

16 pages, 1360 KiB  
Review
Novel Green Approaches for the Preparation of Gold Nanoparticles and Their Promising Potential in Oncology
by Tanima Bhattacharya, Debashrita Das, Giselle A. Borges e Soares, Prasun Chakrabarti, Zhaoquan Ai, Hitesh Chopra, Madalin Alexandru Hasan and Simona Cavalu
Processes 2022, 10(2), 426; https://doi.org/10.3390/pr10020426 - 21 Feb 2022
Cited by 18 | Viewed by 3746
Abstract
The difficulty of achieving targeted drug delivery following administration of currently marketed anticancer therapeutics is a still a concern. Metallic nanoparticles (NPs) developed through nanotechnology breakthroughs appear to be promising in this regard. Research studies pertaining to gold NPs have indicated their promising [...] Read more.
The difficulty of achieving targeted drug delivery following administration of currently marketed anticancer therapeutics is a still a concern. Metallic nanoparticles (NPs) developed through nanotechnology breakthroughs appear to be promising in this regard. Research studies pertaining to gold NPs have indicated their promising applicability in cancer diagnosis, drug delivery and therapy. These NPs have also recently paved the path for precise drug delivery and site-specific targeting. Our review paper thus highlights the scope and impact of biogenetically generated gold nanoparticles (NPs) in cancer therapy. In a critical, constructive, and methodical manner, we compare the advantages offered by gold NPs over other metal NPs. Moreover, we also focus on novel ‘greener’ strategies that have been recently explored for the preparation of gold NPs and shed light on the disadvantages of conventional NP synthesis routes. Future prospects pertaining to the use of gold NPs in oncotherapy and domains that require further investigation are also addressed. Full article
(This article belongs to the Special Issue Application of Nanoparticles in Cancer Therapy)
►▼ Show Figures

Figure 1

19 pages, 2150 KiB  
Review
The Potential Role of Nanoparticles as an Anticancer Therapy in the Treatment of Rectal Cancer
by Mohamed Abbas and Mohammed S. Alqahtani
Processes 2021, 9(12), 2172; https://doi.org/10.3390/pr9122172 - 02 Dec 2021
Cited by 2 | Viewed by 1757
Abstract
Nanotechnology is a rapidly developing science and is applied in a variety of diagnostic and treatment technologies. Colorectal cancer is one of the deadliest human diseases, and hence, wide research is underway regarding its preventative measures. This review demonstrated that “nano” drug delivery [...] Read more.
Nanotechnology is a rapidly developing science and is applied in a variety of diagnostic and treatment technologies. Colorectal cancer is one of the deadliest human diseases, and hence, wide research is underway regarding its preventative measures. This review demonstrated that “nano” drug delivery systems have successfully transferred pharmaceutical drug particles at the nanoscale as compared to larger particles. Research has shown a higher rate of disease progression among patients who receive conventional drugs compared to those who were given nanoscale drugs. However, the behavior of the cellular components differs from the performance of larger cellular components of the same type; these differences are due to the physical interactions between the nanoparticles (NPs). The review aimed to discuss several recent research studies focused on delivering NPs for the treatment of colorectal cancer (CRC). The reviewed experiments have primarily compared the use of NPs alone or with the addition of an anticancer drug or nanocarriers. These three research methods may help solve past problems and propose new future approaches for colorectal cancer by utilizing the available nanotechnologies. Furthermore, the review illustrated the underlying idea behind NP carriers and stem cell delivery that can be used to create a rapid delivery system for stem cells. Full article
(This article belongs to the Special Issue Application of Nanoparticles in Cancer Therapy)
►▼ Show Figures

Figure 1

16 pages, 1872 KiB  
Review
Challenges towards Targeted Drug Delivery in Cancer Nanomedicines
by Muhammad Nadeem Hafeez, Christian Celia and Vilma Petrikaite
Processes 2021, 9(9), 1527; https://doi.org/10.3390/pr9091527 - 27 Aug 2021
Cited by 34 | Viewed by 7388
Abstract
Despite cancer nanomedicine celebrates already thirty years since its introduction, together with the achievements and progress in cancer treatment area, it still undergoes serious disadvantages that must be addressed. Since the first observation that macromolecules tend to accumulate in tumor tissue due to [...] Read more.
Despite cancer nanomedicine celebrates already thirty years since its introduction, together with the achievements and progress in cancer treatment area, it still undergoes serious disadvantages that must be addressed. Since the first observation that macromolecules tend to accumulate in tumor tissue due to fenestrated endothelial of vasculature, considered as the “royal gate” in drug delivery field, more than dozens of nanoformulations have been approved and introduced into the practice for cancer treatment. Lipid, polymeric, and hybrid nanocarriers are biocompatible nano-drug delivery systems (NDDs) having suitable physicochemical properties and modulate payload release in response to specific chemical or physical stimuli. Biopharmaceutical properties of NDDs and their efficacy in animal models and humans can significantly affect their impact and perspective in nanomedicine. One of the future directions could be focusing on personalized cancer treatment, considering the heterogeneity and complexity of each patient tumor tissue and the designing of multifunctional targeted NDDs combining synthetic nanomaterials and biological components, like cellular membranes, circulating proteins, RNAi/DNAi, which enforce the efficacy of NDDs and boost their therapeutic effect. Full article
(This article belongs to the Special Issue Application of Nanoparticles in Cancer Therapy)
►▼ Show Figures

Figure 1

16 pages, 617 KiB  
Review
Controlled Drug Delivery Vehicles in Veterinary Oncology: State-of-the-Art and Future Directions
by Patricia de Faria Lainetti, Fernanda Zuliani, Antonio Fernando Leis-Filho, Ricardo Henrique Fonseca Alves and Carlos Eduardo Fonseca-Alves
Processes 2020, 8(5), 541; https://doi.org/10.3390/pr8050541 - 05 May 2020
Cited by 2 | Viewed by 2756
Abstract
Controlled drug delivery systems can be used to carry several anticancer agents, including classical chemotherapeutic agents such as doxorubicin, paclitaxel or cisplatin, and are also used for the encapsulation of tyrosine kinase inhibitors and monoclonal antibodies. Usually, the controlled systems are used to [...] Read more.
Controlled drug delivery systems can be used to carry several anticancer agents, including classical chemotherapeutic agents such as doxorubicin, paclitaxel or cisplatin, and are also used for the encapsulation of tyrosine kinase inhibitors and monoclonal antibodies. Usually, the controlled systems are used to decrease drug toxicity, increase local drug concentration or target specific organs or systems. In dogs, liposomal doxorubicin is the most known controlled drug delivery vehicle in veterinary medicine. However, several antitumor drugs can be encapsulated within these systems. Since the delivery vehicles are a relatively new topic in veterinary oncology, this review aims to discuss the current knowledge regarding the controlled drug delivery vehicles and discuss the current challenges and future direction of its use in veterinary oncology. Full article
(This article belongs to the Special Issue Application of Nanoparticles in Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop